The analysis of host pathogen interaction in the intravesical BCG therapy

• Project/Area Number: 21890029
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Single-year Grants
• Research Field: Urology
• Research Institution: University of Tsukuba
• Principal Investigator: MIYAZAKI Jun University of Tsukuba, 大学院・人間総合科学研究科, 講師 (10550246)
• Project Period (FY): 2009 – 2010
• Project Status: Completed (Fiscal Year 2010)
• Budget Amount: ¥2,587,000 (Direct Cost: ¥1,990,000、Indirect Cost: ¥597,000); Fiscal Year 2010: ¥1,222,000 (Direct Cost: ¥940,000、Indirect Cost: ¥282,000); Fiscal Year 2009: ¥1,365,000 (Direct Cost: ¥1,050,000、Indirect Cost: ¥315,000)
• Keywords: BCG / 膀胱がん / 膀胱内注入療法 / 膀胱癌 / リポソームベクター / BCGCWS

Research Abstract

The induction of surface NKG2D ligands by R8-liposome-BCG-CWS rendered cancer cells more susceptible to cytolysis by lymphokine-activated killer cells. T24 bladder cancer cells, even when cultured singly in the absence of immune cells, can directly respond to R8-liposome-BCG-CWS. The results obtained in the present study may therefore indicate a novel adoptive immunotherapy against bladder cancers.

Research Products

• [Journal Article] The liposome-incorporating cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guein can directly enhance the susceptibility of cancer cells to lymphokine-activated killer cells through up-regulation of natural-killer group2, member D ligands. (2011)
  • Author(s): Miyazaki J, Kawai K, Kojima T, Oikawa T, Joraku A, Shimazui T, Nakaya A, Yano I, Nakamura T, Harashima H, Akaza H
  • Journal Title: BJU Int (in press)
  • Peer Reviewed
• [Journal Article] The liposome-incorporating cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guein can directly enhance the susceptibility of cancer cells tolymphokine-activated killer cellsthrough up-regulation of natural-killer group 2, member D ligands (2011)
  • Author(s): Jun Miyazaki, Koji Kawai, Takahiro Kojima, Takehiro Oikawa, Akira Joraku, Toru Shimazui, Akihiro Nakaya, Ikuya Yano, Takashi Nakamura, Hideyoshi Harashima, Hideyuki Akaza
  • Journal Title: British Journal of Urology International
  • Peer Reviewed
• [Journal Article] BCG cell wall skeleton内包リポソームベクターによるマウス膀胱癌治療モデル (2010)
  • Author(s): 常楽晃、宮崎淳、中谷彰洋、中村孝司、河合弘二、矢野郁也、原島秀吉、赤座英之
  • Journal Title: 泌尿器外科 23(2) Pages: 184-186
• [Journal Article] Immunoprotection against murine bladder carcinoma by octaarginine-modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette-Guerin. (2009)
  • Author(s): Joraku A, Homhuan A, Kawai K, Yamamoto T, Miyazaki J, Kogure K, Yano I, Harashima H, Akaza H
  • Journal Title: BJU Int 103 Pages: 686-686
  • Peer Reviewed
• [Presentation] BCG-CWS搭載オクタアルギニンリポソーム製剤膀胱内注入によるBBN発癌ラットの治療効果について (2010)
  • Author(s): 宮崎淳、河合弘二、常楽晃、中村孝司、原島秀吉、小濱秀康、矢野郁也、赤座英之
  • Organizer: 第3回BCG注入療法研究会
  • Place of Presentation: 東京
  • Year and Date: 2010-11-26
• [Presentation] BCG cell wall skeleton内包リポソームベクターによるマウス膀胱癌治療モデル (2009)
  • Author(s): 常楽晃、宮崎淳、中谷彰洋、中村孝司、河合弘二、矢野郁也、原島秀吉、赤座英之
  • Organizer: 第2回BCG注入療法研究会
  • Place of Presentation: 東京
  • Year and Date: 2009-11-20
• [Book] 8.泌尿器領域の臨床応用研究:BCG細胞壁骨格成分(BCG-CWS)搭載多機能ナノ構造体による膀胱癌ワクチンの開発(遺伝子医学MOOK17) (2010)
  • Author(s): 宮崎淳、河合弘二、常楽晃、赤座英之、原島秀吉、矢野郁也
  • Publisher: メディカルドゥ社
• [Book] 遺伝子医学MOOK17 8.泌尿器領域の臨床応用研究:BCG細胞壁骨格成分(BCG-CWS)搭載多機能ナノ構造体による膀胱癌ワクチンの開発 (2010)
  • Author(s): 宮崎淳、河合弘二、常楽晃、赤座英之、原島秀吉、矢野郁也
  • Total Pages: 70
  • Publisher: 株式会社メディカルドゥ